News | November 04, 2011

New Study Shows Miracor’s PICSO System Improves Myocardial Perfusion

November 4, 2011—Miracor Medical Systems GmbH announced that data will be reported during next week’s Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific meeting in San Francisco. The data show that the PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) system is safe and feasible during elective percutaneous coronary intervention (PCI) using a femoral vein approach.

The PICSO procedure was performed successfully on 10 patients by Prof. Jan Piek, M.D., and his group at the Academic Medical Center, Amsterdam, Netherlands; the procedure was part of the Prepare PISCO study of stable angina patients. Based on these clinical results, Miracor will soon initiate the Prepare RAMSES study in acute coronary syndrome patients.

“In spite of a successful primary PCI, suboptimal myocardial reperfusion occurs in approximately 30 percent of STEMI patients, and this occurrence is strongly correlated with unfavorable outcomes for patients,” said Piek. “Our study demonstrates that PICSO significantly increased the redistribution of blood into the ischemic myocardium, which is very encouraging as we look to enroll patients into the multi-centre ‘Prepare RAMSES’ study,” he added.

Prof. Piek’s results will be presented during a special spotlight session on ‘Approaches to Reperfusion Injury and Enhancing Myocardial Recovery’ moderated by Mitchell W. Krucoff, M.D., (Duke University Medical Centre, Durham, N.C.) and Holger Thiele, M.D. (University of Leipzig Medical Center, Germany)

Timely myocardial reperfusion using primary PCI remains the most effective treatment strategy for limiting infarct size, reducing left ventricular remodeling, and improving clinical outcomes following ST-segment elevation myocardial infarction (STEMI). Despite optimum primary PCI, the mortality and morbidity following a STEMI event remains sizable. Clearly, primary PCI alone is not enough to eliminate the risk for future cardiovascular events.

Paradoxically, the process of restoring coronary blood flow can in itself exacerbate the myocardial injury. Recent studies have also shown that reduced door-to-balloon time does not reduce mortality in STEMI patients. The PICSO system offers a new approach to reduce myocardial injury and to revitalize ischemic myocardium, thereby providing a cardioprotective effect called cardioprotected PCI (cPCITM).

Initial clinical results show positive effects on MACE, restenosis rates, and long-term event-free survival. The system consists of the PICSO Impulse Console and the disposable, single-use PICSO Impulse Catheter.

For more information: www.miracormedical.com

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init